Intestinal Lymphatic Transport of Halofantrine Occurs After Oral Administration of a Unit-Dose Lipid-Based Formulation to Fasted Dogs

AbstractPurpose. To examine whether the small quantities of lipid present in unit-dose microemulsion formulations comprising medium- (C8-10) or long-chain (C18) glyceride lipids can stimulate the intestinal lymphatic transport of halofantrine (Hf), a model lymphatically transported drug. Methods. Hf (50 mg) was administered to thoracic lymph duct- and cephalic vein-cannulated fasted greyhound dogs. Drug was formulated as a single soft gelatin capsule containing approximately 1 g of a microemulsion preconcentrate based on either medium- or long-chain glycerides. Thoracic lymph was collected, and systemic plasma samples taken over 10 h postdose. Results. The extent of lymphatic transport of Hf after administration of the long-chain lipid formulation was high (28.3% of dose), and significantly higher than that seen after administration of the medium-chain formulation (5.0% of dose). Plasma levels of Hf were not significantly different across the two formulations when assessed by AUC0-10h. Conclusions. This is the first study to demonstrate that the small amounts of lipid present within a single lipid-based dose form can support substantial intestinal lymphatic transport in the fasted state. Furthermore, microemulsions based on long-chain glycerides appear to be more effective with respect to lymphatic transport than the equivalent medium-chain formulation.

[1]  C. Porter,et al.  Uptake of drugs into the intestinal lymphatics after oral administration , 1997 .

[2]  G. Edwards,et al.  Animal models for the study of intestinal lymphatic drug transport. , 2001, Advanced drug delivery reviews.

[3]  C. Porter,et al.  Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. , 2000, Journal of pharmaceutical sciences.

[4]  G. Edwards,et al.  A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs. , 2002, Journal of pharmaceutical sciences.

[5]  C. Porter,et al.  Desbutylhalofantrine: Evaluation of QT Prolongation and Other Cardiovascular Effects after Intravenous Administration In Vivo , 2003, Journal of cardiovascular pharmacology.

[6]  G. Edwards,et al.  Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine , 1998 .

[7]  C. Porter,et al.  A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions. , 1995, Journal of pharmaceutical and biomedical analysis.

[8]  C. Porter Drug delivery to the lymphatic system. , 1997, Critical reviews in therapeutic drug carrier systems.

[9]  K. Isselbacher,et al.  Very low density lipoproteins in intestinal lymph: origin, composition, and role in lipid transport in the fasting state. , 1969, The Journal of clinical investigation.

[10]  D. Capuzzi,et al.  Intestinal triglycerides are derived from both endogenous and exogenous sources. , 1985, The American journal of physiology.

[11]  D. Hauss,et al.  Targeted lymphatic transport and modified systemic distribution of CI-976, a lipophilic lipid-regulator drug, via a formulation approach , 1994 .

[12]  J. Dressman,et al.  Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. , 1997, Journal of pharmaceutical sciences.

[13]  C. Porter,et al.  Model systems for intestinal lymphatic transport studies. , 1996, Pharmaceutical biotechnology.

[14]  C. Porter,et al.  Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion. , 1996, Journal of pharmaceutical sciences.

[15]  K. Isselbacher,et al.  Very low density lipoproteins in intestinal lymph: role in triglyceride and cholesterol transport during fat absorption. , 1969, The Journal of clinical investigation.

[16]  C. Mansbach,et al.  Factors influencing triacylglycerol delivery into mesenteric lymph. , 1985, The American journal of physiology.

[17]  C. Porter,et al.  The formulation of Halofantrine as either non-solubilizing PEG 6000 or solubilizing lipid based solid dispersions: physical stability and absolute bioavailability assessment. , 2000, International journal of pharmaceutics.

[18]  V. Stella,et al.  Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules , 1986 .

[19]  G. Edwards,et al.  A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. , 2001, Journal of pharmaceutical sciences.